Citius is dedicated to building a successful pharmaceutical company by partnering to develop and commercialize innovative, efficacious, and cost-effective products that address compelling market opportunities.

To learn more about our capabilities and opportunities for partnership, please contact us at

Two of our product candidates have been developed by clinicians and technologists at the MD Anderson Cancer Center. In 2016, Citius acquired a worldwide license for Mino-Lok®, the first and only product in development to salvage infected Central Venous Catheters. In January 2019, Citius acquired a worldwide license for Mino-Wrap, potentially the first and only product for the prevention of infections associated with post-mastectomy implants.

Brooklyn ImmunoTherapeutics Logo

In 2020, we partnered with Novellus Therapeutics Ltd. (acquired by Brooklyn ImmunoTherapeutics, Inc. in July 2021), a Cambridge, Massachusetts-based cell engineering company to create NoveCite Inc., a majority-owned subsidiary of Citius. NoveCite is initially focused on developing, manufacturing and commercializing a unique induced mesenchymal stem cell platform for the treatment of patients with acute respiratory distress syndrome (ARDS), including as a result of COVID-19.

Eisai logo

In September 2021, Citius acquired an exclusive license to develop and commercialize a late-stage cancer immunotherapy for which Dr. Reddy’s Laboratories SA (in association with Eisai Co. Ltd) was completing a fully-enrolled Phase 3 pivotal trial in persistent or recurrent CTCL. Eisai retained responsibility for completing the Pivotal trial for an initial CTCL indication and the associated chemistry, manufacturing and controls activities through the filing of a BLA with the U.S. Food and Drug Administration (FDA).